Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073953 · ClinicalTrials.gov registry record · Phase 1
Primaquine Enantiomers in G6PD Deficient Human Volunteers
A Phase 1 study of G6PD Deficiency, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04073953 is a Phase 1 study of G6PD Deficiency that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04073953, a Phase 1 study of G6PD Deficiency, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPQ
- DRUG SPQ
Study Locations (1)
Mississippi
- University of Mississippi - University
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04073953
The ClinicalTrials.gov registry entry for NCT04073953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi, Oxford, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with G6PD Deficiency appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04073953 reports 1 study location spanning 1 distinct geographic area - top geographies include Mississippi.
Frequently Asked Questions
What is clinical trial NCT04073953 about?
NCT04073953 is a clinical study titled "Primaquine Enantiomers in G6PD Deficient Human Volunteers". This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability of primaquine enantiomers and placebo over the course of 5 days.
What is the current status of trial NCT04073953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-01. Estimated completion is 2023-09-01.
What conditions does trial NCT04073953 study?
This clinical trial studies the following conditions: G6PD Deficiency.
What interventions are being tested in trial NCT04073953?
The interventions under investigation include: Placebo (DRUG), RPQ (DRUG), SPQ (DRUG).
Who is sponsoring clinical trial NCT04073953?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04073953 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for G6PD Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.